fashion -WSS

fashion

author：Wikipedia 2025-09-30 20:35:34 - browse：8

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Families look for replacement for GSK asthma drug Flovent

hotspot

WSS

Harvard's David Sinclair gets blowback over aging

Senate panel eyes new effort on drug shortages

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Analysis of telehealth claims data suggest service duplication

A new approach to psychiatric drug development

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

explore

fashion

hotspot

United colonoscopy coverage change 'may cost lives,' doctors say

Chan Zuckerberg Biohub Chicago to focus on inflammation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

For AI in health care standards, federal regulators join with industry group

Heart attack and stroke risk calculators need revising

Phenylephrine and the overlooked value of the placebo effect

Heart attack and stroke risk calculators need revising

Bristol 'take

ChatGPT in medicine: STAT answers readers' burning questions

A Q&A with the global head of Boehringer Ingelheim's innovation unit

focus

Bill would stop addiction treatment from triggering child abuse inquiry

For AI in health care standards, federal regulators join with industry group

Why Talkspace is targeting Medicare, a tricky market

Chemotherapy drug shortage eases slightly but still widespread

Change Healthcare: What is it, why does its cyberattack matter?

VC firm General Catalyst wants to buy a health system

hotspot

knowledge

entertainment

knowledge